Analyzing biomarkers in patients with gastric adenocarcinoma receiving immunotherapy and chemotherapy
Predictive Biomarker Analysis and Model Construction of Tislelizumab Combined With Chemotherapy for Perioperative Treatment of G/GEJ Adenocarcinoma: A Single-center, Observational Study
Xijing Hospital · NCT05508399
This study is testing if combining immunotherapy with chemotherapy can help people with advanced stomach cancer and aims to find out which patients might benefit the most from this treatment.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 28 (estimated) |
| Ages | 18 Years to 80 Years |
| Sex | All |
| Sponsor | Xijing Hospital (other) |
| Drugs / interventions | chemotherapy, immunotherapy |
| Locations | 1 site (Xi'an, Shaanxi) |
| Trial ID | NCT05508399 on ClinicalTrials.gov |
What this trial studies
This study focuses on patients with locally advanced gastric and gastroesophageal junction adenocarcinoma, exploring the effects of combining immunotherapy with chemotherapy as a perioperative treatment. It aims to analyze biomarkers through DNA panel and RNA sequencing to better understand the potential benefits of this combined approach. The study is observational and seeks to gather data on the efficacy of PD-1 monoclonal antibody therapy in conjunction with standard chemotherapy. By investigating these biomarkers, the study hopes to identify which patients may benefit most from this treatment strategy.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18-80 with histologically confirmed locally advanced gastric or gastroesophageal junction adenocarcinoma.
Not a fit: Patients whose biological specimens do not meet detection standards or who have factors that may lead to study termination may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved survival rates and treatment strategies for patients with gastric adenocarcinoma.
How similar studies have performed: Other studies have shown promise in using immunotherapy for gastric adenocarcinoma, but this specific approach is still being explored.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Aged 18-80 (including 18 and 80); 2. G/GEJ adenocarcinoma confirmed by basic ultrasound gastroscopy, enhanced CT (PET/CT), MRI or diagnostic laparoscopy; 3. Biopsy histologically confirmed adenocarcinoma 4. As assessed by the investigator, patients who are qualified for receiving PD-1 mab combined with chemotherapy neoadjuvant therapy; 5. Patients who volunteer to participate in this study and sign the informed consent, with good compliance and cooperation in the acquisition of biological specimens. Exclusion Criteria: 1. Patients whose biological specimens do not meet the detection standards; 2. In the judgment of the investigator, the patients with factors that might have caused the study to be terminated.
Where this trial is running
Xi'an, Shaanxi
- Xijing Hospital of Digestive Diseases — Xi'an, Shaanxi, China (RECRUITING)
Study contacts
- Study coordinator: Gang Ji, Doctoral
- Email: xijingweichang@163.com
- Phone: +8618153227717
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Locally Advanced Gastric Adenocarcinoma, PD-1